Octreotide improves survival in cirrhotic portal hypertension
The long term use of vasoactive drugs as adjuvant treatment to endoscopic sclerotherapy or ligation to reduce the risk of variceal rebleeding and death after the early control of acute variceal haemorrhage has been mooted. In a randomised controlled trial Jenkins et al compared long term octreotide combined with injection sclerotherapy with injection sclerotherapy alone in patients with cirrhotic portal hypertension. It was associated with a significant reduction in variceal rebleeding and an improvement in survival.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
StumbleUpon 
Technorati What's this?
This Article
- Respond to this article
- Alert me when this article is cited
- Alert me when responses are posted
- Alert me when a correction is posted
Services
- Email this article to a friend
- Find similar articles in BMJ
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
Related Content
Bookmark with
What's new
Latest blogs
Find BMJ on:
Services
Tools
Online poll
Resources
Rapid responses for this article
There are no rapid responses for this article. Print issues
